دورية أكاديمية
P36 Numeta G13% preterm neonatal parenteral nutrition solution - a licensed all-in-one triple chamber, ready to use and terminally sterilised parenteral nutrition for preterm newborn infants
| العنوان: | P36 Numeta G13% preterm neonatal parenteral nutrition solution - a licensed all-in-one triple chamber, ready to use and terminally sterilised parenteral nutrition for preterm newborn infants |
|---|---|
| المؤلفون: | Moreno, Mar, McCormick, Kenny, Macfarlane, Lindsey, Scrivens, Alexandra |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2020 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Sutton Coldfield, UK |
| الوصف: | Aims We aim to evaluate the efficacy and safety of Numeta G13%E preterm neonatal parenteral nutrition (PN) in our neonatal population. In September 2017 a National Patient Safety Alert (NPSA) highlighted the risk of harm to babies when lipid was mistakenly run at the rate intended for the aqueous component resulting in significant lipid overdose. Although we have worked to implement many of the alert’s recommendations, we feel we can avoid this risk further by using an all-in-one PN solution.1 Numeta meets current nutritional guidelines as per British Association of Perinatal Medicine (BAPM) but this project allows comparison of outcomes important to both patient and service between those achieved with our current regimen and those with the all-in-one regimen.2 Methods We carried out a quality improvement project from April 2018 to April 2019. We collected data from 330 babies in our neonatal unit during six months before (154 babies) and after (176 babies) the adoption of the all-in-one solution. Our previous PN regimen consisted of a ‘menu’ of aqueous bags (starter, maintenance, ‘light’ and bespoke) and a separate lipid solution. All of them were suitable for peripheral or central administration. Numeta came with similar choices: starter, maintenance -for central administration only- and ‘lite’ and Numeta peripheral, suitable for peripheral administration. Bespoke bags were also available if clinically indicated. We set out our desired outcomes and measured parameters accordingly: Patient outcomes |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://adc.bmj.com/cgi/content/short/105/9/e25-aTest; http://dx.doi.org/10.1136/archdischild-2020-NPPG.45Test |
| DOI: | 10.1136/archdischild-2020-NPPG.45 |
| الإتاحة: | https://doi.org/10.1136/archdischild-2020-NPPG.45Test http://adc.bmj.com/cgi/content/short/105/9/e25-aTest |
| حقوق: | Copyright (C) 2020, BMJ Publishing Group Ltd |
| رقم الانضمام: | edsbas.EB2F33DB |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/archdischild-2020-NPPG.45 |
|---|